Radiology 2021 May 25:204112. Epub 2021 May 25.
From the Department of Diagnostic and Interventional Radiology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany (D.D.); Lunenfeld-Tanenbaum Research Institute, Sinai Health System, 600 University Ave, Toronto, ON, Canada M5G 1X5 (D.D., G.M.H., X.D., E.S.M., A.Z., M.A.H.); Joint Department of Medical Imaging, University Health Network, Sinai Health System and University of Toronto, Toronto, ON, Canada (D.D., G.M.H., S.G., E.S.M., A.T., M.A.H.); Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada (N.F., R.H., G.K., A.Z., A.F., N.P.); Department of Pathology, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada (T.v.d.K.); and Department of Surgery, Division of Urology, Mount Sinai Hospital, Toronto, ON, Canada (A.Z.).
Background In validation studies, risk models for clinically significant prostate cancer (csPCa; Gleason score ≥3+4) combining multiparametric MRI and clinical factors have demonstrated poor calibration (over- and underprediction) and limited use in avoiding unnecessary prostate biopsies. Purpose MRI-based risk models following local recalibration were compared with a strategy that combined Prostate Imaging Data and Reporting System (PI-RADS; version 2) and prostate-specific antigen density (PSAd) to assess the potential reduction of unnecessary prostate biopsies. Materials and Methods This retrospective study included 385 patients without prostate cancer diagnosis who underwent multipara-metric MRI (PI-RADS category ≥3) and MRI-targeted biopsy between 2015 and 2019. Read More